Trial · NCT01080300
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline. | G-ER 1800 mg | Baseline LOCF Average Daily Frequency at Week 4 | -6.72 | 95% Confidence Interval -7.24 to -6.19 | hot flashes |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline. | Sugar Pill | Baseline LOCF Average Daily Frequency at Week 4 | -5.01 | 95% Confidence Interval -5.54 to -4.49 | hot flashes |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline. | G-ER 1800 mg | Baseline LOCF Average Daily Frequency at Week 12 | -7.64 | 95% Confidence Interval -8.21 to -7.07 | hot flashes |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline. | Sugar Pill | Baseline LOCF Average Daily Frequency at Week 12 | -6.50 | 95% Confidence Interval -7.07 to -5.94 | hot flashes |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline. | G-ER 1800 mg | Baseline LOCF Average Daily Severity at Week 4 | -0.42 | 95% Confidence Interval -0.51 to -0.33 | scores on a scale |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline. | Sugar Pill | Baseline LOCF Average Daily Severity at Week 4 | -0.22 | 95% Confidence Interval -0.31 to -0.13 | scores on a scale |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline. | G-ER 1800 mg | Baseline LOCF Average Daily Severity at Week 12 | -0.65 | 95% Confidence Interval -0.77 to -0.52 | scores on a scale |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline. | Sugar Pill | Baseline LOCF Average Daily Severity at Week 12 | -0.46 | 95% Confidence Interval -0.58 to -0.34 | scores on a scale |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline. | G-ER 1800 mg | -8.99 | 95% Confidence Interval -9.71 to -8.27 | hot flashes | |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline. | Sugar Pill | -7.91 | 95% Confidence Interval -8.62 to -7.19 | hot flashes | |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline. | G-ER 1800 mg | -0.86 | 95% Confidence Interval -1.03 to -0.69 | scores on a scale | |
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline. | Sugar Pill | -0.64 | 95% Confidence Interval -0.81 to -0.47 | scores on a scale | |
| Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period. | G-ER 1800 mg | Baseline LOCF Proportion at Week 12 | 173 | Participants | |
| Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period. | Sugar Pill | Baseline LOCF Proportion at Week 12 | 130 | Participants | |
| Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period. | G-ER 1800 mg | Baseline LOCF Proportion at Week 24 | 156 | Participants | |
| Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period. | Sugar Pill | Baseline LOCF Proportion at Week 24 | 114 | Participants | |
| Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period. | G-ER 1800 mg | Baseline LOCF Proportion at Week 12 | 173 | Participants | |
| Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period. | Sugar Pill | Baseline LOCF Proportion at Week 12 | 122 | Participants | |
| Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period. | G-ER 1800 mg | Baseline LOCF Proportion at Week 24 | 159 | Participants | |
| Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period. | Sugar Pill | Baseline LOCF Proportion at Week 24 | 124 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01080300/results